![Sean Ainsworth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sean Ainsworth
Directeur/Membre du Conseil chez
OPUS GENETICS, INC.
Fortune : 1 M $ au 31/05/2026
Profil
Sean Ainsworth was the founder of Compendia Bioscience, Inc. (founded 2006), Ray Therapeutics, Inc. (founded 2021) where the title held was Chairman, RetroSense Therapeutics LLC (founded 2009) where the title held was Chairman & Chief Executive Officer, and Ainsworth Bioconsulting LLC (founded 2004) where the title held was Principal.
Mr. Ainsworth is currently Chairman & Chief Executive Officer at Immusoft Corp.
since 2018 and Lead Independent Director at Opus Genetics, Inc. since 2018.
Former positions include Chief Executive Officer at Genevivo LLC from 2007 to 2008 and Executive Director-Clinical Development at Allergan UC from 2016 to 2017.
Education includes an MBA from Washington University in St. Louis conferred in 2002 and an undergraduate degree from the University of California San Diego conferred in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/04/2026 | 321 692 ( 0,4% ) | 1 M $ | 31/05/2026 |
Postes actifs de Sean Ainsworth
| Sociétés | Poste | Début |
|---|---|---|
| OPUS GENETICS, INC. | Directeur/Membre du Conseil | 01/04/2018 |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Provides disease curing services through immune cells | Directeur Général | 05/01/2018 |
Anciens postes connus de Sean Ainsworth
| Sociétés | Poste | Fin |
|---|---|---|
| ALLERGAN PLC | Corporate Officer/Principal | 01/01/2017 |
RetroSense Therapeutics LLC
 RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology Operates as a biotechnology company that focuses on developing gene therapy | Directeur Général | 01/01/2016 |
Ainsworth Bioconsulting LLC | Fondateur | 01/06/2012 |
Genevivo LLC | Directeur Général | 01/01/2008 |
Ray Therapeutics, Inc.
 Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops optogenetic gene therapies for patients with blinding diseases | Fondateur | - |
Formation de Sean Ainsworth
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
94
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RetroSense Therapeutics LLC
RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology Operates as a biotechnology company that focuses on developing gene therapy | Health Technology |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Provides disease curing services through immune cells | Health Services |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes pharmaceuticals, devices, biological, surgical & regenerative medicine products | Health Technology |
Compendia Bioscience, Inc.
 Compendia Bioscience, Inc. Information Technology ServicesTechnology Services Provides information solutions for oncology drug discovery | Technology Services |
Ocuphire Pharma, Inc.
 Ocuphire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals for eye disorders | Health Technology |
Ainsworth Bioconsulting LLC | |
Genevivo LLC | |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops optogenetic gene therapies for patients with blinding diseases | Commercial Services |
